In this episode, David interviews psychiatrist, main researcher behind the first US Phase II trial of MDMA-assisted psychotherapy, and Senior Medical Director at MAPS Public Benefit Corporation: Dr. Michael Mithoefer; and Research Group Lead at the University of Zurich, and Principal Clinical Biomarker Lead at Boehringer Ingelheim, Katrin Preller, Ph.D. Mithoefer, Preller (and David) are […]
The post PT453 – Neuroplasticity, Individualized Integration, and Psychedelic Medicine – Israel 2023 appeared first on Psychedelics Today.
